EGFR and lung adenocarcinoma: In this study, we survey the DNA alterations of EGFR signaling proteins in solid tumors represented in The Cancer Genome Atlas (TCGA) and are FDA-approved for EGFR inhibitor treatment [8]: pancreatic adenocarcinoma (PAAD), lung adenocarcinoma (LUAD) [23], lung squamous cell carcinoma (LUSC) [24], HNSCC [25], and colon adenocarcinoma (COAD) [26].